TIDMPYC

RNS Number : 1218S

Physiomics PLC

06 July 2020

6 July 2020

Physiomics plc

("Physiomics") or (the "Company")

Director dealing

Physiomics reports that Dr Jim Millen, CEO, has transferred 85,715 ordinary shares of 0.4p each in the capital of the Company ("Ordinary Shares"), acquired during the recently placing, announced on 27 May 2020, to his account with The Share Centre for nil consideration, effective 2 July 2020. The beneficial ownership of the Ordinary Shares remains unchanged and accordingly, Dr Millen remains interested in 530,356 Ordinary Shares representing approximately 0.55% of the Company's issued share capital .

PDMR/PCA FCA Transaction Notification

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                              Dr Jim Millen 
     --------------------------------  ------------------------------------- 
 2.   Reason for the Notification 
     ----------------------------------------------------------------------- 
 a)   Position/status                   Chief Executive Officer 
     --------------------------------  ------------------------------------- 
 b)   Initial notification/amendment    Initial notification 
     --------------------------------  ------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                              Physiomics plc 
     --------------------------------  ------------------------------------- 
 b)   LEI                               213800A71DSZ6ABMTQ91 
     --------------------------------  ------------------------------------- 
 4.   Details of the transaction(s):section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv)each place where transactions have been 
       conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the Financial      Ordinary shares of 0.4p each in the 
       instrument, type of instrument    share capital of the Physiomics plc 
     --------------------------------  ------------------------------------- 
      Identification code               ISIN: GB00BDR6W943 
     --------------------------------  ------------------------------------- 
 b)   Nature of the Transaction         Transfer to broking account 
     --------------------------------  ------------------------------------- 
 c)   Price(s) and volume(s)             Price(s)    Volume(s) 
                                          N/A         85,715 
                                                     ---------- 
     --------------------------------  ------------------------------------- 
 d)   Aggregated information            N/A - single issuance 
       Aggregated volume Price 
     --------------------------------  ------------------------------------- 
 e)   Date of the transaction           2 July 2020 
     --------------------------------  ------------------------------------- 
 f)   Place of the transaction          London Stock Exchange, AIM Market 
                                         (XLON) 
     --------------------------------  ------------------------------------- 
 

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0)20 3764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC ) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHRFMPTMTTMMBM

(END) Dow Jones Newswires

July 06, 2020 05:00 ET (09:00 GMT)